Contents
Alaska is home to many reputable clinical research facilities, like Alaska Clinical Research Center, LLC, and Alaska Cancer Research & Education Center.
State experts collaborate to conduct culturally responsive and efficient health research to address the unique needs of every patient. All research projects are overseen by independent committees that make sure every aspect of the study produces flawless results.
Clinical Trials For Disease Areas in Alaska
Experts in Alaska take part in a wide range of clinical research areas. They study arctic medicine, traditional healing practices, health disparities, infectious diseases, mental health, and the effects of environmental factors on health.
Some clinical research trials in Alaska test new experimental treatments for cancer. While others take a more comprehensive look at already approved medications and their effect on different patients.
A recent report by the Alaska Native Tribal Health Consortium showed that Alaska Natives have the world’s highest known rate of one specific cancer – colorectal cancer. This report includes more than 50 years of data that can ultimately help assess long-term cancer trends and save lives.
Want to take part in clinical and academic research? Here is a list of upcoming and ongoing trials that can help.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +9 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Regional Hospital, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +8 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +8 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: Previously Treated Non-Small Cell Lung Cancer
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +8 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: Multiple Myeloma
The Alaska Oculocardiac Reflex Study
Recruiting
Observation study monitoring vital signs and anesthetic variables particularly heart rate during prospective, ocular manipulation and specifically uniform tension on extra ocular muscles during strabismus surgery.
\*IRB approval from 1992 covered in letter from then IRB chair Dr. Judith Whitcomb, Anchorage, Alaska (letter 10/2020).\*
Observation study monitoring vital signs and anesthetic variables particularly heart rate during prospective, ocular manipulation and specifically uniform tension on extra ocular muscles during strabismus surgery.
\*IRB approval from 1992 covered in letter from then IRB chair Dr. Judith Whitcomb, Anchorage, Alaska (letter 10/2020).\* Read Less
Gender:
ALL
Ages:
Between 1 month and 100 years
Trial Updated:
07/30/2024
Locations: Alaska Children's EYE & Strabismus, Anchorage, Alaska
Alaska Children's EYE & Strabismus, Anchorage, Alaska
Conditions: Bradycardia, Strabismus
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +8 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Recruiting
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach... Read More
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +8 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Fairbanks Memorial Hospital, Fairbanks, Alaska
Conditions: Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC). Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Alaska Women's Cancer Care, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Conditions: Uterine Serous Carcinoma
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +7 locations
Anchorage Associates in Radiation Medicine, Anchorage, Alaska
Anchorage Radiation Therapy Center, Anchorage, Alaska
Alaska Breast Care and Surgery LLC, Anchorage, Alaska
Alaska Oncology and Hematology LLC, Anchorage, Alaska
Alaska Women's Cancer Care, Anchorage, Alaska
Anchorage Oncology Centre, Anchorage, Alaska
Katmai Oncology Group, Anchorage, Alaska
Providence Alaska Medical Center, Anchorage, Alaska
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Recruiting
The purpose of this post-market study is to evaluate the real-world experience of Nevro's Spinal Cord Stimulation (SCS) therapy in patients with chronic, intractable leg pain due to painful diabetic neuropathy (PDN). This is a multicenter, prospective, observational global study, that will partner diabetes management teams with pain physicians to provide an interdisciplinary treatment regimen for PDN patients. Outcomes will be assessed via standardized assessments.
The purpose of this post-market study is to evaluate the real-world experience of Nevro's Spinal Cord Stimulation (SCS) therapy in patients with chronic, intractable leg pain due to painful diabetic neuropathy (PDN). This is a multicenter, prospective, observational global study, that will partner diabetes management teams with pain physicians to provide an interdisciplinary treatment regimen for PDN patients. Outcomes will be assessed via standardized assessments. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Neuroversion, Inc., Anchorage, Alaska
Neuroversion, Inc., Anchorage, Alaska
Conditions: Diabetic Neuropathy, Painful
Paid Clinical Trials in Alaska
Paid clinical trials in Alaska help doctors find better treatments and answer specific scientific questions that can improve patient care. These trials provide ways how to treat, detect, and prevent various diseases.
With AK paid clinical trials, volunteers get compensation for their contribution. Compensation comes in the form of monetary and non-monetary gain.
Clinical Trials For Health Volunteers in Alaska
Research teams in Alaska owe much of their success to health volunteers who selflessly dedicate their time and energy to provide valuable data. Volunteers are the heart and soul of Alaska’s research community.
With their contribution, experts can learn more about the state’s environment, health, and culture, and create innovative solutions that can benefit everyone involved.
Here is a list of trials that can help you make a change.
No trials could be found at this time
Medical Discoveries and Innovation in Alaska
Alaska clinical research has long pushed the boundaries of healthcare and improved the well-being of its diverse population. Many of today’s innovations and discoveries come from the state. Here is a list of some of the most impactful discoveries.
- Indigenous Research Program: The Alaska Indigenous Research Program (AKIRP) allowed experts to incorporate traditional healing practices into modern medicine. This innovative approach helps tailor current medical treatment to the patient’s needs.
- Wildlife-Transmitted Disease Studies: Alaska’s unique ecosystem has provided a natural laboratory for the study of diseases transmitted by wildlife. These include conditions like Lyme disease and hantavirus. Research in this area has helped us better understand zoonotic diseases and how to prevent them.
- Genomic Research in Rare Population: Alaska’s remote and genetically distinct populations have been the focus of genetic research. The data collected helped study rare diseases and genetic variations that can benefit medical treatment.
Why Alaska Is A Great Place For Clinical Research
Alaska is the perfect location for measuring disparities in care. Here 59.3% of the population is White, 14.9% is American Indian, 7.5% is Hispanic, 7.1% is Multiracial, 6.4% is Asian, 3.2% is Black, and 1.6% is Native Hawaiian.